PMID- 20485287
OWN - NLM
STAT- MEDLINE
DCOM- 20100701
LR  - 20220310
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Print)
IS  - 0007-0920 (Linking)
VI  - 102
IP  - 12
DP  - 2010 Jun 8
TI  - Phase II study of capecitabine as palliative treatment for patients with 
      recurrent and metastatic squamous head and neck cancer after previous 
      platinum-based treatment.
PG  - 1687-91
LID - 10.1038/sj.bjc.6605697 [doi]
AB  - BACKGROUND: Platinum-based therapy (PBT) is the standard therapy for recurrent 
      and/or metastatic head and neck cancer (HNC), but the incidence of recurrence 
      remains high. This study evaluates the efficacy and tolerability of capecitabine 
      as palliative monotherapy for recurrent HNC previously treated with PBT. METHODS: 
      Patients aged 18-75 years, with Eastern Cooperative Oncology Group performance 
      status 0-2, squamous HNC with locoregional and/or metastatic recurrence 
      previously treated with PBT and adequate organ functions, were included. 
      Capecitabine (1.250 mg m(-2) BID) was administered on days 1-14 every 21 days for 
      at least two cycles. RESULTS: A total of 40 male patients with a median age of 58 
      years were analysed. All patients received a median number of four cycles of 
      capecitabine (range: 1-9) and the median relative dose intensity was 91%. Seven 
      patients were not evaluable for response. Overall response rate was 24.2%. Median 
      time to progression and overall survival were 4.8 and 7.3 months, respectively. 
      Haematological adverse events (AEs) grade 3/4 were reported in six patients. Most 
      common grade 3/4 non-haematological AEs were asthenia (12.5%), palmar-plantar 
      eritrodisestesia (10%), mucositis (10%), dysphagia (10%) and diarrhoea (7.5%). 
      CONCLUSIONS: Capecitabine seems to be an active, feasible and well-tolerated mode 
      of palliative treatment for advanced HNC patients who have previously received 
      PBT schedules.
FAU - Martinez-Trufero, J
AU  - Martinez-Trufero J
AD  - Medical Oncology Department of University Hospital Miguel Servet Hospital, Paseo 
      de Isabel La Catolica 1-3, 50009 Zaragoza, Spain. jmtrufero@seom.org
FAU - Isla, D
AU  - Isla D
FAU - Adansa, J C
AU  - Adansa JC
FAU - Irigoyen, A
AU  - Irigoyen A
FAU - Hitt, R
AU  - Hitt R
FAU - Gil-Arnaiz, I
AU  - Gil-Arnaiz I
FAU - Lambea, J
AU  - Lambea J
FAU - Lecumberri, M J
AU  - Lecumberri MJ
FAU - Cruz, J J
AU  - Cruz JJ
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100518
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Platinum Compounds)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Capecitabine
MH  - Carcinoma, Squamous Cell/*drug therapy/pathology/secondary
MH  - Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Disease Progression
MH  - Fluorouracil/adverse effects/*analogs & derivatives/therapeutic use
MH  - Head and Neck Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Palliative Care
MH  - Platinum Compounds/administration & dosage
PMC - PMC2883700
EDAT- 2010/05/21 06:00
MHDA- 2010/07/02 06:00
PMCR- 2010/06/08
CRDT- 2010/05/21 06:00
PHST- 2010/05/21 06:00 [entrez]
PHST- 2010/05/21 06:00 [pubmed]
PHST- 2010/07/02 06:00 [medline]
PHST- 2010/06/08 00:00 [pmc-release]
AID - 6605697 [pii]
AID - 10.1038/sj.bjc.6605697 [doi]
PST - ppublish
SO  - Br J Cancer. 2010 Jun 8;102(12):1687-91. doi: 10.1038/sj.bjc.6605697. Epub 2010 
      May 18.